{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:51:04Z","timestamp":1782550264998,"version":"3.54.5"},"reference-count":21,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceutical Company Limited"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Success of gene therapy relies on the durable expression and activity of transgene in target tissues. In vivo molecular imaging approaches using positron emission tomography (PET) can non-invasively measure magnitude, location, and durability of transgene expression via direct transgene or indirect reporter gene imaging in target tissues, providing the most proximal PK\/PD biomarker for gene therapy trials. Herein, we report the radiosynthesis of a novel PET tracer [18F]AGAL, targeting alpha galactosidase A (\u03b1-GAL), a lysosomal enzyme deficient in Fabry disease, and evaluation of its selectivity, specificity, and pharmacokinetic properties in vitro. [18F]AGAL was synthesized via a Cu-catalyzed click reaction between fluorinated pentyne and an aziridine-based galactopyranose precursor with a high yield of 110 mCi, high radiochemical purity of &gt;97% and molar activity of 6 Ci\/\u00b5mol. The fluorinated AGAL probe showed high \u03b1-GAL affinity with IC50 of 30 nM, high pharmacological selectivity (\u226550% inhibition on &gt;160 proteins), and suitable pharmacokinetic properties (moderate to low clearance and stability in plasma across species). In vivo [18F]AGAL PET imaging in mice showed high uptake in peripheral organs with rapid renal clearance. These promising results encourage further development of this PET tracer for in vivo imaging of \u03b1-GAL expression in target tissues affected by Fabry disease.<\/jats:p>","DOI":"10.3390\/molecules28207144","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T10:36:56Z","timestamp":1697625416000},"page":"7144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiosynthesis and Early Evaluation of a Positron Emission Tomography Imaging Probe [18F]AGAL Targeting Alpha-Galactosidase A Enzyme for Fabry Disease"],"prefix":"10.3390","volume":"28","author":[{"given":"Talakad G.","family":"Lohith","sequence":"first","affiliation":[{"name":"Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2137-5242","authenticated-orcid":false,"given":"Charalambos","family":"Kaittanis","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9082-9514","authenticated-orcid":false,"given":"Anthony P.","family":"Belanger","sequence":"additional","affiliation":[{"name":"Molecular Cancer Imaging Facility, Dana Farber Cancer Institute, Boston, MA 02210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-4861","authenticated-orcid":false,"given":"Shin Hye","family":"Ahn","sequence":"additional","affiliation":[{"name":"Molecular Cancer Imaging Facility, Dana Farber Cancer Institute, Boston, MA 02210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Sandoval","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-0119","authenticated-orcid":false,"given":"Lawrence","family":"Cohen","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girija","family":"Rajarshi","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5168-7582","authenticated-orcid":false,"given":"Wanida","family":"Ruangsiriluk","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwana","family":"Islam","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Winkelmann","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McQuade","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kok, K., Zwiers, K.C., Boot, R.G., Overkleeft, H.S., Aerts, J., and Artola, M. (2021). Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions. Biomolecules, 11.","DOI":"10.3390\/biom11020271"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tuttolomondo, A., Simonetta, I., Riolo, R., Todaro, F., Di Chiara, T., Miceli, S., and Pinto, A. (2021). Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810088"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1021\/ja507040n","article-title":"Potent and selective activity-based probes for GH27 human retaining alpha-galactosidases","volume":"136","author":"Willems","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1039\/C5OB00532A","article-title":"Galacto configured N-aminoaziridines: A new type of irreversible inhibitor of beta-galactosidases","volume":"13","author":"Alcaide","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10139","DOI":"10.1021\/jo051645q","article-title":"A short synthesis of (+)-cyclophellitol","volume":"70","author":"Hansen","year":"2005","journal-title":"J. Org. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1021\/ja202610x","article-title":"Galacto-configured aminocyclitol phytoceramides are potent in vivo invariant natural killer T cell stimulators","volume":"133","author":"Harrak","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12272-001-1197-2","article-title":"A (18)F-labeled glucose analog: Synthesis using a click labeling method and in vitro evaluation","volume":"31","author":"Kim","year":"2008","journal-title":"Arch. Pharm. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11307-013-0644-9","article-title":"Evaluation of [(18)F]-CP18 as a PET imaging tracer for apoptosis","volume":"15","author":"Su","year":"2013","journal-title":"Mol. Imaging Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"756724","DOI":"10.3389\/fphar.2021.756724","article-title":"Exploring Carbohydrates for Therapeutics: A Review on Future Directions","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sodano, F., Cristiano, C., Rolando, B., Marini, E., Lazzarato, L., Cuozzo, M., Albrizio, S., Russo, R., and Rimoli, M.G. (2022). Galactosylated Prodrugs: A Strategy to Improve the Profile of Nonsteroidal Anti-Inflammatory Drugs. Pharmaceuticals, 15.","DOI":"10.3390\/ph15050552"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells","volume":"175","author":"Artursson","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/jcpt.13764","article-title":"Clinical pharmacokinetics of nadolol: A systematic review","volume":"47","author":"Kalsoom","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrd3187","article-title":"Coexistence of passive and carrier-mediated processes in drug transport","volume":"9","author":"Sugano","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1124\/dmd.122.000842","article-title":"Metabolism and Disposition of [(14)C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors","volume":"50","author":"Bolleddula","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1124\/dmd.122.000836","article-title":"Sinusoidal Uptake Determines the Hepatic Clearance of Pevonedistat (TAK-924) as Explained by Extended Clearance Model","volume":"50","author":"Sandoval","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200002000-00029","article-title":"Role of P-glycoprotein in drug disposition","volume":"22","author":"Tanigawara","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: Regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_19","first-page":"414","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/00498254.2017.1397812","article-title":"Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles","volume":"48","author":"Shi","year":"2018","journal-title":"Xenobiotica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187231210792928279","article-title":"P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor","volume":"4","author":"Yang","year":"2010","journal-title":"Drug Metab. Lett."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/20\/7144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:08:45Z","timestamp":1760130525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/20\/7144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":21,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["molecules28207144"],"URL":"https:\/\/doi.org\/10.3390\/molecules28207144","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]}}}